Thus, anti-G-CSF treatment of Plcg2S707Y/+ mice rescued the clinical and laboratory features of established APLAID, improving weight gain, spleen size, lifespan and B cell abnormalities. Here, CSF3 is linked to autoinflammation-PLCG2-associated antibody deficiency-immune dysregulation.